Two global trials published online in the New England Journal of Medicine (NEJM) found that the addition of Medtronic's (Dublin) Solitaire stent thrombectomy procedure to current pharmaceutical treatment significantly reduced disability in patients suffering stroke. These trials confirmed the findings of three previous trials also published in NEJM, the company noted. Medtronic inherited the Solitaire device through its $42.9 billion Covidien acquisition.